Boditech Med Inc

Boditech Med Inc maintains a strong liquidity position, with a current ratio of 5.51, indicating that the company has more than five times the current assets to cover its current liabilities. The company's liquidity is further supported by a cash and equivalents balance of KRW 36,279,272,270, which is a significant portion of its total assets. The debt-to-equity ratio of 0.06 suggests a conservative capital structure, with minimal reliance on debt financing.

In terms of profitability, Boditech Med Inc reported a net income of KRW 9,671,150,390 for the latest period, translating to a return on equity (ROE) of 4.64% and a return on assets (ROA) of 3.87%. These figures are in line with the industry's preferred metrics, which emphasize operational efficiency and asset utilization. The company's operating income of KRW 9,383,929,480 and gross profit of KRW 22,195,361,330 indicate a healthy margin structure, suggesting effective cost management and pricing power.

The company's revenue is primarily concentrated in its domestic market, with a significant portion derived from the sale of diagnostic equipment and reagents. While the company has a presence in international markets, the majority of its revenue is generated within South Korea. This concentration may expose the company to regional economic fluctuations and regulatory changes.

Looking ahead, Boditech Med Inc is projected to maintain a stable growth trajectory, with a free cash flow of KRW 9,401,923,470 and a capital expenditure of KRW -5,193,508,950. The company's operating cash flow of KRW 11,167,984,790 supports its ongoing operations and reinvestment needs. The company's financial performance suggests a conservative approach to capital allocation, with a focus on maintaining liquidity and profitability.

The risk assessment for Boditech Med Inc indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is relatively stable. The company's low debt-to-equity ratio and strong cash reserves further mitigate financial risk. However, the company's reliance on a single geographic market and the competitive nature of the healthcare equipment industry may pose long-term challenges.

Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core business of diagnostic equipment and reagents, with no major new product launches or strategic acquisitions reported in the latest filings. The company's financial performance and operational stability suggest a consistent and predictable business model.

The company maintains a low debt-to-equity ratio of 0.06, matching the cohort median and indicating low leverage risk.

Revenue grew 37.3% year-over-year to 162 billion KRW, demonstrating strong top-line expansion momentum in the latest period.

Cash conversion of 1.15 exceeds the cohort median of 0.79, highlighting superior efficiency in generating cash from operations.

Dilution, liquidity, and credit risks are all assessed as low, suggesting a stable financial foundation for investors.

Return on equity of 4.6% remains low, suggesting limited efficiency in generating profits relative to shareholder equity.

Long-term debt increased to 17.7 billion KRW, rising significantly from 6.9 billion KRW in fiscal year 2022.

Revenue KRW 31.22B; Operating income KRW 1.76B.

• ▍Revenue KRW 31.22B
• ▍Operating income KRW 1.76B
• ▍Net margin 15.5%

Revenue KRW 37.59B; Operating income KRW 8.83B.

• ▍Revenue KRW 37.59B
• ▍Operating income KRW 8.83B
• ▍Net margin 16.2%

Revenue KRW 36.25B; Operating income KRW 9.38B.

• ▍Revenue KRW 36.25B
• ▍Operating income KRW 9.38B
• ▍Net margin 26.7%

Revenue KRW 138.16B, +2,9% YoY; Operating income −9,8% YoY.

• ▍Revenue KRW 138.16B, +2,9% YoY
• ▍Operating income −9,8% YoY
• ▍Net income +5,1% YoY
• ▍Free cash flow −27,6% YoY
• ▍Net margin 19.7%

Revenue KRW 134.22B, +13,7% YoY; Operating income +16,7% YoY.

• ▍Revenue KRW 134.22B, +13,7% YoY
• ▍Operating income +16,7% YoY
• ▍Net income +7,4% YoY
• ▍Free cash flow +124,3% YoY
• ▍Net margin 19.3%

Revenue KRW 157.71B; Operating income KRW 51.86B.

• ▍Revenue KRW 157.71B
• ▍Operating income KRW 51.86B
• ▍Net margin 28.1%